Synairgen appoints Dr Marcin Mankowski as CMO
UK respiratory disease focussed biotech Synairgen (LSE: SNG) today announced the appointment of Dr Marcin Mankowski as chief medical officer (CMO), effective immediately.
Dr Mankowski is a seasoned pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience and a strong background in infectious diseases and respiratory medicine. He joins Synairgen on a full-time basis having worked with the company as acting CMO and a clinical trials consultant since 2018.
Prior to joining Synairgen, Dr Mankowski was co-founder and chief executive at tranScrip Ltd, a leading contract drug development business, where he played an integral strategic role in both driving investment as well as leading a vast range of projects across all stages of drug development and multiple therapy areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze